SpringWorks Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
Rhea-AI Summary
SpringWorks Therapeutics (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focusing on severe rare diseases and cancer, has announced its plans to report third quarter 2024 financial results on Tuesday, November 12, 2024. The company will host a live conference call and webcast at 8:30 a.m. ET to discuss the financial results and provide recent business updates.
Interested parties can join the live webcast and view the accompanying slides by clicking on the provided link. To participate in the conference call by phone, pre-registration is required through another provided link. Registered participants will receive a dial-in number and conference code for access. A replay of the webcast will be available for a time on the company's Investors & Media section of their website.
Positive
- None.
Negative
- None.
STAMFORD, Conn., Oct. 22, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Tuesday, November 12, 2024 to report its third quarter financial results and discuss recent business updates.
To join the live webcast and view the corresponding slides, please click here. To participate in the live conference call by phone, please click here to pre-register. Registered participants will then be provided with a dial-in number and conference code to access the call. A replay of the webcast will be available for a limited time following the event on the Investors & Media section of the Company’s website at https://ir.springworkstx.com.
About SpringWorks Therapeutics
SpringWorks is a commercial-stage biopharmaceutical company applying a precision medicine approach to developing and delivering life-changing medicines for people with severe rare diseases and cancer. OGSIVEO® (nirogacestat), approved in the United States for the treatment of adult patients with progressing desmoid tumors who require systemic treatment, is the Company’s first FDA-approved therapy. SpringWorks also has a diversified targeted therapy pipeline spanning solid tumors and hematological cancers, with programs ranging from preclinical development through advanced clinical trials. In addition to its wholly owned programs, SpringWorks has also entered into multiple collaborations with innovators in industry and academia to unlock the full potential for its portfolio and create more solutions for patients in need.
For more information, visit www.springworkstx.com and follow @SpringWorksTx on X (formerly Twitter), LinkedIn, and YouTube.
Contacts:
Investors
investors@springworkstx.com
Media
media@springworkstx.com
FAQ
When will SpringWorks Therapeutics (SWTX) report its Q3 2024 financial results?
What time is SpringWorks Therapeutics' (SWTX) Q3 2024 earnings call scheduled?
How can investors access SpringWorks Therapeutics' (SWTX) Q3 2024 earnings webcast?
Will there be a replay available for SpringWorks Therapeutics' (SWTX) Q3 2024 earnings call?
